Suppr超能文献

应对2019冠状病毒病的前列腺癌放射治疗建议

Prostate Cancer Radiation Therapy Recommendations in Response to COVID-19.

作者信息

Zaorsky Nicholas G, Yu James B, McBride Sean M, Dess Robert T, Jackson William C, Mahal Brandon A, Chen Ronald, Choudhury Ananya, Henry Ann, Syndikus Isabel, Mitin Timur, Tree Alison, Kishan Amar U, Spratt Daniel E

机构信息

Department of Radiation Oncology, Penn State Cancer Institute, Hershey, Pennsylvania.

Department of Therapeutic Radiology/Radiation Oncology, Yale, New Haven, Connecticut.

出版信息

Adv Radiat Oncol. 2020 Apr 1;5(4):659-665. doi: 10.1016/j.adro.2020.03.010. eCollection 2020 Jul-Aug.

Abstract

PURPOSE

During a global pandemic, the benefit of routine visits and treatment of patients with cancer must be weighed against the risks to patients, staff, and society. Prostate cancer is one of the most common cancers radiation oncology departments treat, and efficient resource utilization is essential in the setting of a pandemic. Herein, we aim to establish recommendations and a framework by which to evaluate prostate radiation therapy management decisions.

METHODS AND MATERIALS

Radiation oncologists from the United States and the United Kingdom rapidly conducted a systematic review and agreed upon recommendations to safely manage patients with prostate cancer during the COVID-19 pandemic. A RADS framework was created: remote visits, and avoidance, deferment, and shortening of radiation therapy was applied to determine appropriate approaches.

RESULTS

Recommendations were provided by the National Comprehensive Cancer Network risk group regarding clinical node-positive, postprostatectomy, oligometastatic, and low-volume M1 disease. Across all prostate cancer stages, telemedicine consultations and return visits were recommended when resources/staff available. Delays in consultations and return visits of between 1 and 6 months were deemed safe based on stage of disease. Treatment can be avoided or delayed until safe for very low, low, and favorable intermediate-risk disease. Unfavorable intermediate-risk, high-risk, clinical node-positive, recurrence postsurgery, oligometastatic, and low-volume M1 disease can receive neoadjuvant hormone therapy for 4 to 6 months as necessary. Ultrahypofractionation is preferred for localized, oligometastatic, and low-volume M1, and moderate hypofractionation is preferred for postprostatectomy and clinical node positive disease. Salvage is preferred to adjuvant radiation.

CONCLUSIONS

Resources can be reduced for all identified stages of prostate cancer. The RADS (remote visits, and avoidance, deferment, and shortening of radiation therapy) framework can be applied to other disease sites to help with decision making in a global pandemic.

摘要

目的

在全球大流行期间,必须权衡癌症患者常规就诊和治疗的益处与对患者、工作人员及社会的风险。前列腺癌是放射肿瘤学部门治疗的最常见癌症之一,在大流行背景下高效利用资源至关重要。在此,我们旨在建立评估前列腺放射治疗管理决策的建议和框架。

方法与材料

来自美国和英国的放射肿瘤学家迅速进行了系统综述,并就 COVID-19 大流行期间安全管理前列腺癌患者的建议达成一致。创建了一个 RADS 框架:远程就诊以及应用放疗的避免、推迟和缩短来确定合适的方法。

结果

国家综合癌症网络风险组针对临床淋巴结阳性、前列腺切除术后、寡转移和低容量 M1 疾病提供了建议。在所有前列腺癌阶段,当有可用资源/工作人员时,建议进行远程医疗咨询和复诊。根据疾病阶段,1至6个月的咨询和复诊延迟被认为是安全的。对于极低、低和有利的中危疾病,治疗可避免或推迟至安全时进行。不利的中危、高危、临床淋巴结阳性、术后复发、寡转移和低容量 M1 疾病可根据需要接受4至6个月的新辅助激素治疗。对于局限性、寡转移和低容量 M1,首选超分割放疗,对于前列腺切除术后和临床淋巴结阳性疾病,首选适度分割放疗。挽救性放疗优于辅助放疗。

结论

对于所有确定的前列腺癌阶段均可减少资源。RADS(远程就诊以及放疗的避免、推迟和缩短)框架可应用于其他疾病部位,以帮助在全球大流行中进行决策。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0478/7406779/e68691ef28cc/gr1.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验